This is a prospective natural history cohort study to understand the long term effect of inflammation on vascular and metabolic health in patients with psoriasis. Furthermore, this study will enable the collection of clinical data, tissue and blood in an organized fashion to probe novel inflammatory pathways involved in cardiometabolic disease. Subjects are defined as patients whose diagnosis of psoriasis is clinically confirmed by a referring dermatologist or rheumatologist. Self-referred patients will be seen first by NIH dermatology to confirm the diagnosis of psoriasis prior to enrollment in the longitudinal study. Within the clinical context, this is standard of care whereby a patient is diagnosed with psoriasis when noted to have typical skin findings and associated findings of systemic disease of joints, nails and hair. Most commonly, these diagnoses are made by skin and joint specialists, the main referral sources for the protocol. Severity will be defined as mild, moderate, or severe based on estimated psoriasis body surface area categories. The start of observation time will be the first visit to the NIH Clinical Center in which the subject agrees to longitudinal, regular participation in PACI and gives written informed consent. This screening visit would be the baseline visit. In the event that a subject is not willing to participate in all of the study procedures during the initial screening visit, they will be evaluated at this initial visit, permitted to participate in studies they consent to, but then will not be followed longitudinally in this protocol beyond visit 1. The end of observation time will be four years from entrance into the study (or death). Patients will remain in contact after the initial 4 year observation for occurrence of cardiovascular outcomes. Also, during the course of the study, patients will be instructed to return to the NIH CC if their psoriasis becomes severe (flare). The primary outcome will be vascular inflammation measured by FDG PET CT, that is, FDG uptake within the aorta as measured by standardized uptake value (SUV). Coronary vessel wall area, mean aortic wall thickness and cardiometabolic biomarkers will be secondary outcomes. Exploratory efforts involve assessment of myocardial perfusion to understand whether coronary plaque modifies coronary flow by CCTA, MRI and PET.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
National Heart, Lung, and Blood Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Sorokin, Alexander V; Norris, Paul C; English, Justin T et al. (2018) Identification of proresolving and inflammatory lipid mediators in human psoriasis. J Clin Lipidol 12:1047-1060
Carlucci, Philip M; Purmalek, Monica M; Dey, Amit K et al. (2018) Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight 3:
Sorokin, Alexander V; Domenichiello, Anthony F; Dey, Amit K et al. (2018) Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J Invest Dermatol 138:1518-1528
Lerman, Joseph B; Joshi, Aditya A; Bluemke, David A et al. (2018) Response by Lerman et al to Letters Regarding Article, ""Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study"". Circulation 137:1092-1093
Baumer, Yvonne; Ng, Qimin; Sanda, Gregory E et al. (2018) Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. JCI Insight 3:
Rivers, Joshua P; Powell-Wiley, Tiffany M; Dey, Amit K et al. (2018) Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study. JACC Cardiovasc Imaging 11:349-357
Mehta, Nehal N; Shin, Daniel B; Joshi, Aditya A et al. (2018) Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Circ Cardiovasc Imaging 11:e007394
Ogdie, Alexis; Kay McGill, Neilia; Shin, Daniel B et al. (2018) Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 39:3608-3614
Dey, Amit K; Joshi, Aditya A; Chaturvedi, Abhishek et al. (2017) Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. JAMA Cardiol 2:1013-1018
Mehta, Nehal N; Teague, Heather L; Swindell, William R et al. (2017) IFN-? and TNF-? synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep 7:13831

Showing the most recent 10 out of 36 publications